P
PharosiBio
AI-driven drug discovery company developing therapies for rare and intractable diseases
About PharosiBio
Pharos iBio Co., Ltd. is a clinical-stage biopharmaceutical company based in South Korea that develops treatments for rare and intractable diseases using AI-driven drug discovery. The company's Chemiverse platform combines big data on protein structures and compounds with deep learning to support drug development from target identification through drug candidate generation. Pharos iBio went public on the KOSDAQ exchange in July 2023 and focuses its pipeline on oncology and rare-disease therapeutics.
The pipeline includes PHI-101, a FLT3/CHK2 inhibitor in phase 1 clinical development for acute myeloid leukemia (AML) and platinum-resistant ovarian cancer, with additional studies in triple-negative breast cancer; PHI-201, an early-stage candidate for pancreatic cancer and non-small cell lung cancer; and earlier-stage programmes including PHI-501 for melanoma and refractory colorectal cancer. The company pursues an open-innovation model, working with hospitals, universities and pharmaceutical partners, and operates overseas subsidiaries in the United States and Australia to support global development and collaboration.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- Seoul, South Korea
- Listing
- IPO 2023
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 49.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Disease, Biotech and Pharma, Hard Tech, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | Dec 2025 | $16M | — | DSC Investment · Aju IB Investment · Company K Partners · Korea Investment & Securities | ↗ |
| IPO✓Exit | Jul 2023 | $39M | $39M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $252K | 0% |
| 2025 | $252K | 0% |
| 2024 | $252K | 0% |
| 2023 | $252K | 0% |
| 2022 | $252K | +426.3% |
| 2021 | $48K | -69.6% |
| 2020 | $157K | — |
Growth signals
Latest recorded traffic for PharosiBio is 1.5K monthly website visits, down 42.3% over the last three months. PharosiBio's team grew 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Mirae Asset Venture Investment
DSC Investment
Korea Investment Partners
Company K Partners
Aju IB Investment- KSKorea Investment & Securities
Series B and later6 investors entered at this stage
Solidus Investment
KDB Capital- TMTimefolio Asset Management
- LILSK Investment
UTC Investment
Intops Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PharosiBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PharosiBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.